[ad_1]
East Rutherford, New Jersey, March 18, 2024 /PRNewswire/ — Cambrex, the world’s leading contract development and manufacturing organization (CDMO), today announced that it is nearing the end of its five-year contract. 100 million dollars We moved our investment strategy a year ahead of schedule. The project will add more than 150,000 square feet of production capacity and expansion across 70% of the company’s North American and European drug development and manufacturing network and is expected to be completed by the end of 2024. Investments span all clinical and commercial scales. Manufacturing drug substances involves advanced technology to solve challenges associated with complex molecules.
Following this investment, Cambrex’s flagship API manufacturing facility in Charles City, Iowa, is equipped with more than 25,000 gallons of reactor capacity.
“When we embarked on this initiative, we aligned our investment strategy with the future needs of our pharmaceutical customers. In addition to manufacturing capabilities, we We have also invested in specialized technology.” Tom Loewald, CEO of Cambrex. “We are excited to announce that these features and capabilities are coming to market well ahead of schedule and demonstrate the hard work of our talented site operations and engineering teams.”
in North Americathe five-year investment strategy included expanding production capacity. Charles City, Iowa and High Point, North Carolina, adding clinical and commercial manufacturing suites for low-volume, high-volume, and robust API manufacturing. To support early development programs, Cambrex has expanded its capabilities. Longmont, Colorado, analytical services will be housed in the same facility as drug substance and drug development. Cambrex has also added specialized technology for continuous flow process development and complex synthesis. Waltham, Massachusetts.
in EuropeCambrex has expanded its research and development capabilities. Milan, Italyhas commissioned a new stability storage facility, featuring a new high-potency lab for API process and analytical development Liège, Belgium.
In 2024, Cambrex will complete the final phase of expansion in both areas. North America and EuropeAdds a newly modernized quality control laboratory to Charles City, Iowa Karlskoga will bring into operation two new 6m3-scale production lines, representing a 50% increase in large-scale API manufacturing capacity. Sweden.
With these investments, Cambrex remains well-positioned to support its customers in the development and manufacturing of innovative new treatments that improve human health.
About Cambrex
Cambrex is a leading global contract development and manufacturing organization (CDMO) providing drug substance development and manufacturing throughout the drug lifecycle, as well as comprehensive analytical and IND realization services.
With over 40 years of experience and a team of 2,000 professionals, we serve clients around the world. North America and EuropeCambrex offers a variety of specialized drug substance technologies and capabilities, including continuous flow, controlled materials, solid state science, materials characterization, and highly potent APIs.
Photo: https://mma.prnewswire.com/media/2364291/Cambrex.jpg
Logo: https://mma.prnewswire.com/media/2236065/Cambrex_logo.jpg
Source Cambrex
[ad_2]
Source link
